Abstract
In 2005, the antibodies market was valued at an estimated US$14 billion,
accounting for over 24 percent of the total protein therapeutics market. This
share increased substantially since 2001, when it barely surpassed 13 percent.
Monoclonal antibody (MAbs) therapies have been posting the fastest growth
within the protein therapeutics market. According to Arrowhead Publishers'
report Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline
Insight the value of this market is set to reach more than $16 billion in
2006This growth will continue in the coming years, boosted by a number of new
MAbs on the market, new indications for successful medications, and their
ability to treat conditions and diseases for which there is great unmet need.
Monoclonal Antibody Therapies 2007 provides an analytically-based overview of
the growing market for therapeutic monoclonal antibodies, which represent the
largest segment of protein-based therapeutics. An increasing number of biotech
companies are investing in the MAbs field, mostly in collaboration with major
pharmaceutical companies, to take advantage of this dynamic and growing field.
This report assesses the overall monoclonal antibody market, as part of the
wider protein therapeutics industry. Factors influencing their historical and
future performance - including manufacturing problems and the impact of future
generic competition - are assessed to provide a balanced overview of the
market and key products by major therapeutic categories. Finally, the report
forecasts likely revenue performance of the most successful products in the
next five years, identifying key areas of growth.
Key Features of this report:
- Thorough market analysis of global monoclonal antibody sales, segmented by
product, company, and geographic region
- Financial forecasts for key MAbs on the market as well as promising new
MAbs entering the market
- Analysis of MAb manufacturing issues and their effect on the financial
potential of the therapeutic MAb market
- Profiles of key companies involved in the development and marketing of
therapeutic MAbs
- A review of important happenings in R&D and an evaluation of the upcoming
crop of new MAbs
Who should buy this report?
- Companies with a need to better understand the monoclonal antibody market
and its place in the modern pharmaceutical industry
- Companies interested in understanding the impact and implications of
product placement, lifecycle management and competition in the monoclonal
antibody marketplace
- Pharma and biotech companies wishing to identify potential areas for
partnerships and collaboration in the monoclonal antibody market
| 
View Cart
